Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
Summary: This presentation compared the benefits of TKIs in wet AMD management, focusing on pan-VEGF receptors blockage and extended drug delivery while acknowledging the limitations of current ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results